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To analyze the effects of a short course of methyl-prednisolone pulses (MP) during the sec-
ond week of disease (week-2) in patients with severe coronavirus disease 2019 (COVID-19)
pneumonia.
Methods
Comparative observational study using data collected from routine care at Hospital Universi-
tario Cruces, Barakaldo, Bizkaia, Spain in patients with COVID-19 pneumonia. We com-
pared patients who received week-2-MP (125–250 mg/d x3) with those who did not, with the
end-points time to death and time to death or endotracheal intubation.
Results
We included 242 patients with COVID-19 pneumonia and elevated inflammatory markers at
admission. Sixty-one patients (25%) received week-2-MP. Twenty-two patients (9%) died
and 31 (12.8%) suffered death or intubation. The adjusted HRs for death and death or intu-
bation for patients in the week-2-MP group were 0.35 (95%CI 0.11 to 1.06, p = 0.064) and
0.33 (95%CI 0.13 to 0.84, p = 0.020), respectively. These differences were specifically seen
in the subcohort of patients with a SpO2/FiO2 at day 7 lower than 353 (adjusted HR 0.31,
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95% CI 0.08 to 1.12, p = 0.073 and HR 0.34, 95%CI 0.12 to 0.94, p = 0.038, respectively)
but not in patients with higher SpO2/FiO2. Patients receiving out-of-week-2-MP, non-pulse
glucocorticoids or no glucocorticoids had an increased adjusted risk for both outcomes com-
pared with week-2-MP group: HR 5.04 (95% CI 0.91–27.86), HR 10.09 (95% CI 2.14–
47.50), HR 4.14 (95% CI 0.81–21.23), respectively, for death; HR 7.38 (95% CI 1.86–
29.29), HR 13.71 (95% CI 3.76–50.07), HR 3.58 (95% CI 0.89–14.32), respectively, for
death or intubation. These differences were significant only in the subgroup with low SpO2/
FiO2.
Conclusions
Week-2-MP are effective in improving the prognosis of patients with COVID-19 pneumonia
with features of inflammatory activity and respiratory deterioration entering the second week
of disease. The recognition of this high-risk population should prompt early use of MP at this
point.
Introduction
Beginning in December 2019, a novel coronavirus, designated SARS-CoV-2, has caused an
international outbreak of respiratory illness termed COVID-19 [1, 2]. Glucocorticoids were
banned in the initial recommendations for treating the disease [3]. However, severe lung and
systemic inflammation may take place usually during the second week of disease, being the
main cause of admission to intensive care units, need for mechanical respiratory support and
death [4].
Admission of patients with COVID-19 started at Hospital Universitario Cruces in March
2020, reaching its peak between the 27th of March and early April. An initial period of no use
of glucocorticoids [3] was followed by the administration of non-pulse glucocorticoids and
later methyl-prednisolone pulses (MP) to selected patients. On April 3rd 2020, a joined proto-
col by the services of Infectious Diseases and Internal Medicine included MP in certain scenar-
ios (see Methods).
The aim of this study is to analyse the effects of MP on the clinical course of patients with
COVID-19 pneumonia admitted to the services of Infectious Diseases and Internal Medicine
of Hospital Universitario Cruces. Our working hypothesis was that a short course of MP
administered within the second week after the onset of symptoms (week-2-MP) would
improve the outcome of patients with COVID-19 pneumonia with markers of inflammation
and signs of progressive respiratory deterioration.
Methods
Study design and population
We conducted an observational study using data collected from routine care to assess the effi-
cacy of week-2-MP to treat patients with COVID-19 pneumonia. The protocol was approved
by the Basque Country Research Ethics Committee (code EPA2020032) in accordance with
the Declaration of Helsinki’s guidelines for research in humans. This study has been registered
in the EU PAS Register with the number EUPAS36287.
All patients admitted between March 1st and April 30th to the services of Infectious Diseases
and Internal Medicine, Hospital Universitario Cruces, with a diagnosis of COVID-19
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pneumonia, supported by chest X-ray and/or CT scan informed by skilled radiologists. All
cases were confirmed by positive reverse-transcriptase–polymerase-chain-reaction (RT-PCR)
assay for SARS-CoV-2 in nasopharyngeal swabs, were initially selected for the study. Patients
were excluded if they had no inflammatory markers at admission (see Therapeutic protocols),
died within the first week of symptoms, were admitted to hospital after the end of the second
week, died of causes non-related to COVID-19 infection or were initially admitted to the
Intensive Care Unit.
Therapeutic protocols
Initial management included supportive therapy with fluids and oxygenation with the goal of
an O2 saturation�92%. The antiviral protocol was developed based on the recommendations
by the Spanish Ministry of Health and the Spanish Agency for Medicines and Health Products
(AEMPS) in the weeks prior to April 3, 2020 [5, 6].
Hydroxychloroquine for 5 days associated with lopinavir/ritonavir for 7–10 days were rec-
ommended for all patients with pneumonia. Selected patients with severe pneumonia
-CURB65�2 [7] and/or SpO2 in ambient air O2 <90%- could be treated with remdesivir for
5 to 10 days, at the discretion of the clinician, after enrolment in a clinical trial [8] or as an off-
label drug. Following the recommendations of the World Health Organization (WHO) [3],
glucocorticoids were not used during the initial weeks of the pandemic, unless needed for
comorbid conditions.
After the recognition of the inflammatory phase of COVID-19 pneumonia [4], glucocorti-
coids were empirically given to selected patients with severe disease and positive inflammatory
markers, defined as any of the following: lymphocyte count<800/mm3 (normal 1300–2900),
platelet count<150000/mm3 (normal 135000–150000), ferritin >1000 ng/ml (normal 15–
300), C-reactive protein >100 mg/l (normal 0–11), D-dimer >1000 ng/ml (normal 0–500).
This was an empiric definition, in which the levels of ferritin, CRP and D-dimers well above
the upper normal limit were set taking into account the marked elevation in such parameters
seen in many patients with COVID-19 pneumonia.
Glucocorticoids were initially given at doses around 1 mg/Kg/d during several days and
later as MP, 125 to 250 mg/d for 3 consecutive days, similar to the scheme used in our patients
with systemic autoimmune diseases [9]. Our therapeutic protocol was updated on April 3rd
2020, including the recommendation of MP for patients with COVID-19 pneumonia with
altered/worsening inflammatory parameters (lymphopenia, thrombocytopenia, rising ferritin,
D-dimers and or C-reactive protein) and clinical deterioration, particularly those showing
impending respiratory failure with decreasing SpO2/FiO2 values. MP were encouraged to be
given during the second week after the onset of symptoms, always according to the attending
physician best judgment. This therapeutic protocol remained unchanged until the end of the
study period.
Study variables
All the clinical data were extracted from Hospital Universitario Cruces electronic medical rec-
ords by the study investigators. Databases were accessed to extract the study data between 11th
and 30th May 2020. All data were fully anonymized before the analysis and the Basque Country
Research Ethics Committee waived the requirement for informed consent.
Baseline variables included age, gender, previous diagnosis of diabetes mellitus, obesity
(body mass index�30), arterial hypertension, chronic pulmonary disease, active neoplastic,
neurodegenerative disease or systemic autoimmune disease and immunosuppressive therapy.
The CURB65 scale [7] was calculated at admission and divided into three categories (low,
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medium and high risk). In order to assess severity within the second week of disease, the
SpO2/FiO2 at that point was included in the database. The definition of high inflammatory
state at admission described in the therapeutic protocol in use (see above) was assumed for the
purposes of this study.
Therapeutic variables included the following: lopinavir/ritonavir, hydroxychloroquine,
non-pulse glucocorticoids (including the average daily dose and the number of days of treat-
ment), low molecular weight heparin and MP (including the week of administration, counting
after the onset of symptoms).
Outcomes
We used two primary outcomes: time to death (attributed to COVID-19) and time to death or
endotracheal intubation.
Statistical analysis
Mean and standard deviation or median and interquartile range were used to describe contin-
uous variables, according to their distributional characteristics. Counts and relative frequen-
cies describe categorical variables. The time of onset of symptoms (fever and/or persistent
cough), as reported by the patient, was the time origin for calculation of time to events. Life
tables were used to describe risk of events over the follow-up period, which ended either at the
occurrence of the event of interest, at discharge or at the end of the study follow-up on 20th
May 2020. Kaplan-Meier failure curves with log-rank test were calculated for each of the two
primary outcomes, using the dichotomous variable week-2-MP, yes/no, for group
comparisons.
Adjusted Cox proportional risk models were fitted to assess the effect of the dichotomous
variable week-2-MP as the predictor of main interest. The aforementioned variables were
included in the full model. Likelihood ratio tests were used in a sequential fashion in order to
find a reduced adjusted model containing statistically significant covariates. Hazard ratios
(HR) with 95% confidence intervals were used to estimate the magnitude of the association
between risk predictors and outcomes. Proportionality of hazards was tested through the use
of comparison of adjusted and predicted survival curves and Schoenfeld residuals.
All the univariate and multivariate analyses were repeated after stratification by the median
SpO2/FiO2 at week 2 (equal to 353), in two groups: SpO2/FiO2�353 and>353 (designated as
low SpO2/FiO2 and high SpO2/FiO2), as this variable showed a significant departure from the
proportionality of hazards assumption.
Finally, the Cox analysis was repeated using a four-category predictor in order to better
illustrate the effects of glucocorticoids according to the dose, duration and time of administra-
tion. Patients were divided into 4 groups: a) no-glucocorticoids, i.e. patients not receiving glu-
cocorticoids in any form (n = 122); b) non-pulse glucocorticoids, i.e. patients receiving
glucocorticoids at doses lower than 100 mg/d for periods longer than 3 days (n = 36, with 10 of
them also receiving pulses); c) out-of-week-2-MP, i.e. MP at week 1 or 3, with no additional
glucocorticoids at lower doses (n = 30); d) week-2-MP, i.e. patients receiving MP during week
2, with no additional glucocorticoids at lower doses (n = 54). As our proposed schedule con-
sists of MP with no following tapering scheme, we decided to group all patients receiving non-
pulse courses of glucocorticoids for longer than 3 days into the same category and keeping in
the MP groups those patients receiving only pulses.
Stata 16.1 for Windows was used for all the analyses (StataCorp. 2019. Stata Statistical Soft-
ware: Release 16. College Station, TX: StataCorp LLC.).
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Patient and public involvement
Neither patients nor the public were involved in the conception or conduct of the study.
Results
Three hundred and forty-three patients with COVID-19 pneumonia were initially identified.
Of these, 252 had an inflammatory state at admission; after excluding 2 patients with early
death within the first week of disease course, 2 patients dying with COVID-19 but with death
attributable to terminal cancer and 6 patients admitted after the end of the second week of dis-
ease, 242 patients were selected for the analysis of the primary and secondary outcomes.
Sixty-one patients (25%) received week-2-MP. In addition, 33 patients (14%) received out-
of-week-2-MP (week 1 or 3). The remaining 148 patients (61%) did not receive MP.
Table 1 shows the clinical characteristics of the whole cohort and according to whether or
not patients received week-2-MP.
Outcome: Death
Twenty-two patients (9.1%) died during the study period. The proportion of deceased patients
was lower in the week-2-MP group: 4/61 (6.6%) vs. 18/181 (9.9%). The Kaplan-Meier failure
curves (Fig 1A) showed a non-significant decreased risk of death of patients in the week-2-MP
group (log-rank test, p = 0.102).
The final Cox model showed an adjusted HR for death of 0.35 (95%CI 0.11 to 1.06,
p = 0.064) for patients in the week-2-MP group. Other independent predictors of death
included a previous diagnosis of arterial hypertension, the use of non-pulse glucocorticoids, a
high-risk CURB65 category and SpO2/FiO2 at week 2 (Table 2).
In the subgroup with low SpO2/FiO2, 3/42 (7.1%) week-2-MP patients died vs. 14/80
(17.5%) non week-2-MP patients. The Kaplan-Meier failure curves depicted on Fig 1B showed
a significantly lower mortality among week-2-MP patients (long-rank test, p = 0.041).
The final Cox model in this subcohort showed a protective effect of week-2-MP (HR 0.31,
95% CI 0.08 to 1.12, p = 0.073), with the rest of independent predictors being unchanged from
the whole cohort model.
No differences were seen in the univariate analysis between patients with or without week-
2-MP in the subpopulation with high SpO2/FiO2. Only 5/120 (4%) patients died in this sub-
group. The multivariate Cox model could not identify any significant predictor of the
outcome.
Outcome: Death or intubation
Thirty-one patients (12.8%) suffered death or intubation. Week-2-MP patients had a lower
incidence of the combined outcome: 6/61 (9.8%) vs. 25/181 (13.8%). The Kaplan-Meier failure
curves (Fig 2A) showed a non-significant largest time free of events in patients receiving week
2 MP, (log-rank test p = 0.125).
In the final Cox model, the adjusted HR for week-2-MP was 0.33 (95%CI 0.13 to 0.84,
p = 0.020). The same independent predictors than in the model with death as the outcome var-
iable, with the exception of arterial hypertension, were retained (Table 3).
In the subcohort with low SpO2/FiO2, the combined outcome was met by 5/42 (12%) vs.
20/80 (25%) patients receiving and not receiving, respectively, week-2-MP. The failure curves
on Fig 2B showed a significantly better outcome in the former group (log-rank test, p = 0.032).
In the final Cox model, week-2-MP were beneficial (HR 0.34, 95%CI 0.12 to 0.94,
p = 0.038). The model retained the same final variables than the whole cohort analysis.
PLOS ONE Second week methyl-prednisolone pulses in severe covid 19 pneumonia
PLOS ONE | https://doi.org/10.1371/journal.pone.0239401 September 22, 2020 5 / 17
Six patients suffered the combined outcome in the subcohort of patients with high SpO2/
FiO2. Again, no differences were seen between patients with or without week-2-MP in the uni-
variate or multivariate analysis. However, the use of non-pulse glucocorticoids was associated
with an increased risk for the combined outcome (HR 10.5, 95%CI 0.94 to 116.84, p = 0.056).
Analysis of the four-level glucocorticoid variable
Table 4 depicts the clinical characteristics of the four subgroups.
Table 1. Clinical characteristics of the cohort according to treatment with MP.
VARIABLE Overall (n = 242) Week-2-MP (n = 61) No week-2-MP (n = 181) p-value1
Age (years), mean (sd) 64.4 (14.3) 65.0 (12.1) 64.2 (15.0) 0.702
Male
n (%)
150 (62.0) 40 (65.6) 110 (60.8) 0.504
Follow-up� (days), mean (sd) 17.9 (7.3) 20.7 (6.0) 17.0 (7.5) 0.0007
Diabetes mellitus
n (%)
51 (21.1) 9 (14.8) 42 (23.2) 0.162
Overweight
n (%)
49 (20.3) 10 (16.4) 39 (21.6) 0.386
Hypertension
n (%)
117 (48.4) 33 (54.1) 84 (46.4) 0.299
Chronic bronchopathy
n (%)
62 (25.6) 14 (23.0) 48 (26.5) 0.581
Active cancer
n (%)
26 (10.7) 7 (11.5) 19 (10.5) 0.831
Neurodegenerative disease
n (%)
9 (3.7) 3 (4.9) 6 (3.3) 0.567
Autoimmune disease
n (%)
9 (3.7) 3 (4.9) 6 (3.3) 0.567
Immunosuppressive therapy
n (%)
21 (8.7) 5 (8.2) 16 (8.8) 0.877
CURB65, high risk n. (%) 19 (7.9) 5 (8.2) 14 (7.7) 0.461
Time of symptoms to admission (days) mean (sd) 6.6 (3.2) 7.4 (2.8) 6.3 (3.2) 0.021
Lymphocytes (count/mm3) median (iqr) 800 (580) 680 (480) 815 (575) 0.118
Platelets (count/mm3) median (iqr) 212,000 (144,000) 208,000 (156,000) 213,000 (135,500) 0.703
Ferritin (mg/dl) median (iqr) 543 (807) 824 (919) 481 (723) <0.001
D-dimers (ng/ml), Median (iqr) 500 (1,171) 540 (870) 470 (1,171) 0.224
C-reactive protein (mg/dl)
median (iqr)
79.5 (112.8) 112.3 (89.8) 73.4 (99.9) 0.024
SpO2/FiO2, median (iqr) 380 (160.0) 332 (201.0) 438 (125.0) <0.001
SpO2/FiO2 < 353
n (%)
117 (48.3) 41 (67.2) 76 (42.0) 0.001
Hydroxychloroquine n (%) 224 (92.9) 61 (100) 163 (90.5) 0.013
Days on hydroxychloroquine mean (sd) 6.25 (2.6) 6.8 (2.6) 6.1 (2.6) 0.24
Lopinavir/ritonavir
n (%)
218 (90) 58 (95) 160 (88) 0.13
Betaferon
n (%)
13 (5.3) 1 (1.6) 12 (6.6) 0.13
LMWH
n (%)
225 (92.9) 60 (98.3) 165 (91.26) 0.057
Week-2-MP: methyl-prednisolone pulses in week 2; LMWH: low molecular weight heparin; sd: standard deviation; iqr: interquartile range.
� From disease onset to death, discharge or end of the study period.
https://doi.org/10.1371/journal.pone.0239401.t001
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In the model with mortality as single outcome, week-2-MP patients showed lower mortality
(HR 0.24, 95%CI 0.05 to 1.24, p = 0.088), whilst non-pulse glucocorticoid patients had an
increased risk of death (HR 2.44, 95%CI 0.88 to 6.76, p = 0.087), both compared with patients
with no glucocorticoids. The rest of the model included the same variables than the previous
analysis (Table 5). In the subcohort with low SpO2/FiO2, week-2-MP decreased mortality
compared with no glucocorticoids, HR 0.14, 95%CI 0.02 to 1.28, p = 0.082. The remaining sub-
groups showed non significant differences.
In the model with the combined death or intubation outcome, 2-week-MP were protective
(HR 0.28, 95%CI 0.07 to 1.12, p = 0.072), whilst non-pulse glucocorticoids increased the risk
Fig 1. Kaplan-Meier failure curves, second week methyl-prednisolone pulses (2-MP) vs. no 2-MP. Outcome: death.
(a) Whole cohort (n = 242). Log-rank test, p = 0.102. (b) Patients with low SpO2/FiO2 (n = 122). Log-rank test,
p = 0.041.
https://doi.org/10.1371/journal.pone.0239401.g001
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(HR 3.83, 95%CI 1.52 to 9.68, p = 0.004) vs. patients on no glucocorticoids. The results were
similar in the subcohort with a low SpO2/FiO2: week-2-MP vs. no glucocorticoids, HR 0.20,
95%CI 0.04 to 1.00, p = 0.050; non-pulse glucocorticoids vs. no glucocorticoids, HR 3.06, 95%
CI 1.06 to 8.85, p = 0.039 (Table 6).
None of the analysis in the subcohort with high SpO2/FiO2 at week 2 showed significant
differences between the four therapeutic groups.
The results of the four-level glucocorticoid Cox analysis with 2-week-MP as the main com-
parator are presented in Table 7. Week-2-MP was superior to all the other therapies in order
to prevent both main outcomes. The effects were more marked among patients with low
SaO2/FiO2.
Discussion
This study supports the utility of glucocorticoids to improve the outcome of patients with
COVID-19 pneumonia. Glucocorticoid use, however, should not be indiscriminate, but rather
restricted to patients with laboratory evidence of inflammation and progressing respiratory
compromise, and best used as short-course pulse therapy (125–250 mg/d of methyl-predniso-
lone during 3 days) administered during the second week after the onset of symptoms, where
the hyperinflammatory reaction takes usually place.
By the time the outbreak reached our region in late February 2020, the use of glucocorti-
coids was discouraged by the WHO [3]. This recommendation was based on a review of the
clinical evidence of steroid therapy in other similar viral diseases, such as SARS-Cov-1, Middle
East respiratory syndrome (MERS), influenza and respiratory syncytial virus, and on the idea
that glucocorticoids could actually delay viral clearance [10]. However, an observational study
of 201 patients with COVID-19 pneumonia admitted to Wuhan Jinyintan Hospital published
Table 2. Predictors of death: Final models.
Variable HR (95%CI) p
WHOLE COHORT (n = 242)
Week-2-MP 0.35 (0.11–1.06) 0.064
Non-pulse glucocorticoids 3.01 (1.28–7.14) 0.012
Hypertension 2.89 (0.91–9.17) 0.072
SpO2/FiO2 0.94 (0.91–0.98) 0.001
CURB65
Low risk Reference
Intermediate risk 1.64 (0.55–4.88) 0.371
High risk 7.72 (2.56–23.26) <0.001
PATIENTS WITH SpO2/FiO2�353 (n = 122)
Week-2-MP 0.31 (0.08–1.12) 0.073
Non-pulse glucocorticoids 2.98 (1.09–8.17) 0.034
Hypertension 3.14 (0.84–11.75) 0.089
SpO2/FiO2 0.92 (0.87-0-97) 0.002
CURB65
Low risk Reference
Intermediate risk 1.48 (0.41–5.34) 0.546
High risk 10.29 (2.72–38.94) 0.001
Week-2-MP: methyl-prednisolone pulses in week 2. HR: hazard ratio; CI: confidence interval.
�HR for SpO2/FiO2 is change in hazard for each increase of 10 units in its value.
https://doi.org/10.1371/journal.pone.0239401.t002
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in early March showed a reduced mortality among patients receiving methyl-prednisolone,
although the dose, the duration and the time of administration were not specified [11].
Indeed, new insights into the pathogenesis of the disease seem to support immunoregula-
tion of some kind in patients affected by SARS-Cov-2, with the recognition of an inflammatory
phase of the disease that can lead to extensive lung and multisystemic injury [4]. This second
phase usually takes place during the second week after the onset of symptoms.
Recent data also support the utility of glucocorticoids in COVID-19 disease [12–14]. In an
observational study of 213 patients from Detroit [12], investigators compared patients of two
groups, the standard of care (SOC) and early corticosteroid protocol groups (CP). Patients
Fig 2. Kaplan-Meier failure curves, second week methyl-prednisolone pulses (2-MP) vs. no 2-MP. Outcome: death
or intubation. (a) Whole cohort (n = 242). Log-rank test, p = 0.125. (b) Patients with low SpO2/FiO2 (n = 122). Log-
rank test, p = 0.032.
https://doi.org/10.1371/journal.pone.0239401.g002
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were given a similar median of 40 mg/d of methyl-prednisolone for 3 days, however, the pro-
portion of treated patients (SOC 56.5% vs. CP 68.2%) and the time from symptoms to methyl-
prednisolone administration (SOC 10 days vs. CP 8 days) were different. The combined com-
posite end point (admission to intensive care unit/mechanical ventilation/death) occurred in
54.3% vs. 34.9% (OR 0.45, 95%CI 0.26–0.79) of patients in the SOC and CP, respectively.
A second observational study from Madrid compared 396 patients admitted for COVID-19
treated with glucocorticoids with 67 not treated [13]. In the glucocorticoid-treated group,
methyl-prednisolone was given either at 1 mg/kg/d (78.3%) or as 2 to 4-day pulses, up to 500
mg/d (21.7%) with subsequent tapering in 25% patients. The duration of therapy with 1 mg/
kg/d was not specified. The median time from disease onset to initiation of glucocorticoid was
10 days. This study showed a significant reduction in mortality among glucocorticoid users
(13.9% vs. 23.9%, HR 0.51, 95%CI0.27–0.96), with differences being significant only in the sub-
group classified as moderate-severe disease. There was no difference in mortality between
patients receiving 1 mg/Kg/d or pulses, however, 70 patients received MP a mean of 5 days
after the failure of the 1 mg/kg/d scheme.
The preliminary results from the RECOVERY trial have just been released [15]. Patients
with suspected or confirmed COVID-19 infection were randomised to receive dexamethasone
(n = 2104) or SOC (n = 4321). The dexamethasone protocol consisted of 6 mg/d for up to 10
days, although the actual median number of days was 6, and 7% of SOC patients also received
dexamethasone. The primary outcome, all-cause mortality within 28 days of randomization,
was met by 21.6% patients allocated to dexamethasone vs. 24.6% allocated to usual care (RR
0.83; 95% CI 0.74 to 0.92). The reduction of mortality was only significant in patients receiving
respiratory support. Following the press release of these results, the WHO has already
demanded an increase in dexamethasone production [15].
In contrast, a more recent Brazilian double-blind, randomized, placebo-controlled trial in
patients with clinical or radiological suspicion of COVID-19 pneumonia, with SpO2� 94% at
Table 3. Predictors of death or intubation: Final models.
Variable HR (95%CI) p
WHOLE COHORT (n = 242)
Week-2-MP 0.33 (0.13–0.84) 0.020
Non-pulse glucocorticoids 3.87 (1.87–8.02) <0.001
SpO2/FiO2 0.92 (0.89–0.94) <0.001
CURB65
Low risk Reference
Intermediate risk 1.93 (0.83–4.45) 0.125
High risk 3.65 (1.48–9.02) 0.005
PATIENTS WITH SatO2/FiO2�353 (n = 122)
Week-2-MP 0.34 (0.12–0.94) 0.038
Non-pulse glucocorticoids 3.16 (1.36–7.37) 0.008
SpO2/FiO2� 0.88 (0.83-0-93) <0.001
CURB65
Low risk Reference
Intermediate risk 1.78 (0.69–4.57) 0.234
High risk 3.94 (1.44–10.78) 0.008
Week-2-MP: methyl-prednisolone pulses in week 2. HR: hazard ratio; CI: confidence interval.
�HR for SpO2/FiO2 is change in hazard for each increase of 10 units in its value.
https://doi.org/10.1371/journal.pone.0239401.t003
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Age (years), mean (sd) 62.9 (14.7) 69.0 (13.1) 63.9 (16.4) 64.9 (12.5) 0.159
Male
n (%)
63 (51.6) 29 (80.6) 23 (76.7) 35 (64.8) 0.003
Follow-up (days)�, mean (sd) 15.9 (5.0) 19.5 (10.7) 20.2 (10.7) 20.7 (5.9) <0.001
Diabetes mellitus
(n (%)
25 (20.9) 10 (27.8) 9 (30.0) 7 (13.0) 0.206
Overweight
n (%)
29 (23.8) 5 (13.9) 5 (16.7) 10 (18.5) 0.536
Hypertension
n (%)
51 (41.8) 22 (61.1) 15 (50.0) 29 (53.7) 0.165
Chronic bronchopathy
n (%)
29 (23.8) 15 (41.7) 6 (20.0) 12 (22.2) 0.116
Active cancer
n (%)
15 (12.3) 5 (13.9) 0 (0.0) 6 (11.1) 0.231
Neurodegenerative disease
n (%)
3 (2.5) 1 (2.8) 2 (6.7) 3 (5.6) 0.601
Autoimmune disorder
n (%)
4 (3.3) 3 (8.3) 0 (0.0) 2 (3.7) 0.339
Immunosuppressive therapy
n (%)
10 (8.2) 7 (19.4) 0 (0.0) 4 (7.4) 0.041
Curb65: high risk
n (%)
5 (4.1) 6 (16.7) 5 (16.7) 3 (5.6) 0.040
Time of symptoms to admission (days)
mean (sd)
6.8 (3.1) 5.4 (3.1) 5.4 (3.6) 7.6 (2.7) 0.001
Lymphocytes (count/mm3)
median (iqr)
950 (540) 670 (460) 625 (500) 690 (460) <0.001
Platelets (count/mm3)
median (iqr)
205,000 (116,000) 212,000 (154,500) 228,500 (135,000) 214,500 (165,000) 0.900
Ferritin (mg/dl)
median (iqr)
402 (561) 444 (920) 1231 (1327) 818 (919) <0.001
D-dimers ng/ml
median (iqr)
410 (991) 565 (1,115) 750 (1670) 525 (890) 0.121
C-reactive protein (mg/dl)
median (iqr)
60.1 (109.2) 78.2 (97.5) 110.8 (97.5) 120.6 (94.7) 0.001
SaO2/FiO2
median (iqr)
450.0 (118.1) 445.5 (214.0) 299.5 (344.2) 330.5(206.3) <0.001
SaO2/FiO2 <353
n (%)
43 (35.2) 19 (52.8) 21 (70.0) 35 (64.8) <0.001
Hydroxychloroquine
n (%)
109 (89.3) 32 (88.9) 29 (96.7) 54 (100) 0.227
Days on hidroxicloroquina
mean (sd)
6.0 (2.9) 6.8 (4.0) 6.2 (2.7) 6.9 (2.7) 0.290
Lopinavir-Ritonavir
n (%)
109 (89.3) 31 (83.1) 27 (90.0) 51 (94.4) 0.602
Betaferon
n (%)
8 (6.6) 3 (8.3) 1 (3.3) 1 (1.9) 0.472
LMWH
n (%)
110 (90.2) 32 (88.9) 30 (100) 53 (98.2) 0.076
Week-2-MP: methyl-prednisolone pulses in week 2; LMWH: low molecular weight heparin; sd: standard deviation; iqr: interquartile range.
� From disease onset to death, discharge or end of the study period.
https://doi.org/10.1371/journal.pone.0239401.t004
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room air or need for non-invasive or invasive ventilation reported no benefit from the use of
methyl-prednisolone [16]. They were treated with methyl-prednisolone, 0.5 mg/kg/12h, or
placebo for five days. The 28-day mortality rates in the 393 patients who completed the follow-
up was 37.1% vs. 38.2% in the intervention and placebo groups, respectively. Of note, the
median number of days between disease onset and randomization was 13 days in both groups.
Authors reported, in the subgroup of patients older than 60 years who also had higher levels of
C-reactive protein, a lower mortality among patients treated with methyl-prednisolone.
Thus, a beneficial role of glucocorticoids in patients with severe COVID-19 disease has been
generally found [12–14, 16]. Whether they should be used in short-term pulses (i.e. doses of
methylprednisolone between 100–500 mg/d for 3–4 days) or at lower doses for more prolonged
periods of time is still an open question. The advantages of dexamethasone over methyl-prednis-
olone are not well established; besides the large sample size and the randomised controlled trial
design of the RECOVERY study [14], the difference between the treated and untreated groups
was quantitatively smaller than in the studies using methyl-prednisolone [12, 13]. The time of
administration of glucocorticoids has been variable, although in the Brazilian study, which con-
cluded with mostly negative results, they were administered within the third week of disease in
50% of patients [16]. Thus, specific recommendations about which corticosteroid should be
administered, at what dose, for how long and when in the clinical course, could not be yet made.
Table 5. Predictors of death: final models using the type of glucocorticoid therapy.
Variable HR (95%CI) p
WHOLE COHORT (n = 242)
Glucocorticoid therapy
No glucocorticoids reference
Non-pulse glucocorticoids 2.44 (0.88–6.76) 0.087
Out-of-week-2-MP 1.22 (0.33–4.42) 0.767
Week-2-MP 0.24 (0.05–1.24) 0.088
Hypertension 2.96 (0.92–9.56) 0.069
SpO2/FiO2� 0.94 (0.91–0.97) 0.001
CURB65
Low risk reference
Intermediate risk 1.75 (0.58–5.21) 0.318
High risk 7.66 (2.46–28.85) <0.001
PATIENTS WITH SpO2/FiO2�353 (n = 122)
Glucocorticoid therapy
No glucocorticoids reference
Non-pulse glucocorticoids 2.30 (0.71–7.47) 0.169
Out-of-week-2-MP 1.40 (0.35–5.54) 0.636
Week-2-MP 0.14 (0.02–1.28) 0.082
Hypertension 3.11 (0.78–12.41) 0.108
SaO2/FiO2� 0.91 (0.86–0.96) 0.001
CURB65
Low risk reference
Intermediate risk 1.67 (0.45–6.18) 0.441
High risk 10.85 (2.58–45.56) 0.001
MP: methyl-prednisolone pulses; Week-2-MP: methyl-prednisolone pulses in week 2. HR: hazard ratio; CI:
confidence interval.
�HR here estimates change in hazard by 10 units increase in SpO2/FiO2.
https://doi.org/10.1371/journal.pone.0239401.t005
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Our study confirms that patients with COVID-19 disease with a high inflammatory profile
and respiratory compromise are most likely to benefit from glucocorticoid therapy. In addi-
tion, our study found that only in patients treated in the second week after the onset of symp-
toms seemed MP to be effective. We also observed a clear difference between the use of a short
course of MP and more prolonged reduced doses of glucocorticoids, the former preventing
and the second being associated to an increased risk of both unfavourable outcomes in all
developed models. The presence of unidentified sources of bias cannot be excluded even after
Table 6. Predictors of death or intubation. Final models using the type of glucocorticoid therapy.
Variable HR (95%CI) p
WHOLE COHORT (n = 242)
Glucocorticoid therapy
No glucocorticoids reference
Non-pulse glucocorticoids 3.83 (1.51–9.68) 0.004
Out-of-week-2-MP 2.06 (0.71–6.00) 0.183
Week-2-MP 0.28 (0.07–1.12) 0.072
SpO2/FiO2� 0.92 (0.89–0.95) <0.001
CURB65
Low risk reference
Intermediate risk 2.38 (1.00–5.65) 0.049
High risk 3.98 (1.58–9.89) 0.003
PATIENTS WITH SpO2/FiO2�353 (n = 122)
Glucocorticoid therapy
No glucocorticoids reference
Non-pulse glucocorticoids 3.06 (1.06–8.85) 0.039
Out-of-week-2-MP 1.92 (0.61–6.00) 0.263
Week-2-MP 0.20 (0.04–1.00) 0.050
SpO2/FiO2� 0.88 (0.83–0.93) <0.001
CURB65
Low risk reference
Intermediate risk 2.49 (0.91–6.80) 0.075
High risk 5.00 (1.73–14.47) 0.003
MP: methyl-prednisolone pulses; Week-2-MP: methyl-prednisolone pulses in week 2. HR: hazard ratio; CI:
confidence interval.
�HR here estimates change in hazard by 10 units increase in SaO2/FiO2.
https://doi.org/10.1371/journal.pone.0239401.t006
Table 7. Cox models for death and death or intubation by type of glucocorticoid therapy.
Death Death or intubation
Whole cohort SpO2/FiO2�353 Whole cohort SpO2/FiO2�353
HR (95%CI)� p HR (95%CI)� p HR (95%CI)�� p HR (95%CI)�� p
Week-2-MP reference reference reference reference
Non-pulse glucocorticoids 10.09 (2.14–47.50) 0.003 16.20 (1.86–141.05) 0.012 13.71 (3.76–50.07) <0.001 15.50 (3.14–76.38) 0.001
Out-of-week-2-MP 5.04 (0.91–27.86) 0.064 9.83 (0.78–12.41) 0.044 7.38 (1.86–29.29) 0.004 9.72 (1.91–49.31) 0.006
No glucocorticoids 4.14 (0.81–21.23) 0.088 7.04 (0.78–63.71) 0.082 3.58 (0.89–14.32) 0.072 5.07 (1.00–25.67) 0.050
MP: methyl-prednisolone pulses; Week-2-MP: methyl-prednisolone pulses in week 2. HR: hazard ratio; CI: confidence interval.
�Model adjusted by hypertension, SaO2FiO2 and Curb65 score.
��Model adjusted by SaO2FiO2 and Curb65 score.
https://doi.org/10.1371/journal.pone.0239401.t007
PLOS ONE Second week methyl-prednisolone pulses in severe covid 19 pneumonia
PLOS ONE | https://doi.org/10.1371/journal.pone.0239401 September 22, 2020 13 / 17
statistical adjustment for other prognostic factors and thus we cannot assure this deleterious
effect on non-pulse methyl-prednisolone, moreover in the light of the results of previous stud-
ies. However, the superiority of week-2-MP over all the remaining options was clearly identi-
fied in our cohort. Our study does not support the use of non-pulse glucocorticoids in the
setting of severe COVID-19 pneumonia, either alone or combined with MP.
These findings are actually in agreement with the results seen in patients with systemic
lupus erythematosus and other autoimmune diseases. The activation of the non-genomic way
by MP, given during a short period of time, maximises the anti-inflammatory activity of gluco-
corticoids without relevant side effects [17–19]. On the other hand, doses in the range of 40–
90 mg/d during a period of one week or more are less effective and can increase the risk of
infections. The reason for this is the full activation of the genomic way, which is responsible
for most of the serious secondary effects of glucocorticoids [17–19].
Limitations
The most important limitation of this study is the observational design with a high variability
in the therapeutic schemes, a consequence of the rapidly changing situation during this highly
stressing pandemic. Indeed, the actual number of patients treated with MP was lower than
expected after the approval of the revised protocol. Patients receiving MP also had a more
severe disease. Thus, although the analysis included a high number of potentially predictive
variables in the initial multivariate Cox models, it is possible that some unidentified con-
founder may have influenced our results. We also had a low number of patients meeting the
final endpoints compared with other studies [12–14, 16]. A possible explanation for this is
that, despite the high pressure attained, our hospital did not collapse as many others in Spain.
Despite the consequent limited statistical power, the risk reduction among patients receiving
week-2-MP was consistently between 60–70% for both endpoints in all the models, which sup-
ports a clinically relevant effect.
A critical point in the clinical application of our results is the correct identification of the
point of disease onset, in order to make the correct evaluation and starting MP, if needed,
early in the second week. This is not always easy, since non-specific symptoms may precede
the fully symptomatic phase of the disease by several days and because some patients even with
radiological features of severe pneumonia can be oligosymptomatic [20]. Thus, a thorough
anamnesis must be made at admission with specific questions regarding the starting date of
fever, persistent cough and/or dyspnea.
Conclusion
This study confirms that MP, 125–250 mg/d for 3 consecutive days given during the second
week of disease without subsequent tapering, improve the prognosis of patients with COVID-
19 pneumonia, features of inflammatory activity and respiratory deterioration. Our results
open the door to a more rational and planned management of patients with COVID-19. Those
with negative inflammatory markers and normal SpO2 seem to have a good prognosis, thus
clinical observation monitoring oxygen saturation (even at home), could be appropriate. On
the other hand, those approaching the second week of disease with worsening inflammatory
markers and respiratory failure would greatly benefit from a short course of MP, which could
not only be life-saving, but also help avoid the overload of critical care units.
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